Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | CCR5 | P51681 | 5/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795249 | 0.85 | HTR2A (0.47) | HTR2AOPRM1CCR5UBE2MDCUN1D1 | |
| SCHEMBL784814 | 0.85 | CCR5 (0.60) | CCR5NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2794028 | 0.84 | HTR2A (0.46) | HTR2AOPRM1CCR5UBE2MDCUN1D1 | |
| Hydrochloric Acid SCHEMBL2795250 | 0.84 | HTR2A (0.46) | HTR2AOPRM1CCR5UBE2MDCUN1D1 | |
| SCHEMBL2791615 | 0.84 | HTR2A (0.51) | HTR2ADCUN1D1CHRM3 | |
| SCHEMBL20780570 | 0.83 | HTR2A (0.65) | HTR2A | |
| Hydrochloric Acid SCHEMBL2791610 | 0.83 | HTR2A (0.50) | HTR2ADCUN1D1CHRM3 | |
| SCHEMBL30802466 | 0.82 | SMN1; SMN2 (0.49) | CCR5NPC1RAB9ASMN1; SMN2CHRM2 | |
| SCHEMBL2907313 | 0.81 | THRB (0.49) | OPRM1CCR5UBE2MDCUN1D1NPC1 | |
| SCHEMBL785198 | 0.80 | SIGMAR1 (0.58) | HTR2ACCR5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| EP-2164829-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150089-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | PDF, PEPD, DPEP1 | HTR2A 4650/4885OPRM1 4668/4885CCR5 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.